What is the revenue and EPS growth rate for Ashland year over year?

Did Ashland beat or miss consensus estimates last quarter?

What were the key takeaways from Ashland's earnings call?

What factors drove the changes in Ashland's revenue and profit?

What were the key takeaways from Ashland’s earnings call?

What is Ashland's latest dividend and current dividend yield?

What guidance did Ashland's management provide for the next earnings period?

What is the market's earnings forecast for Ashland next quarter?

- **Resilient Performance**: Life Sciences and Personal Care segments showed strength, offsetting Specialty Additives challenges.
- **Innovation Driven Growth**: TVO technologies and super wetting agents gaining traction in pharma and coatings.
- **Operational Resilience**: Despite delays, cost-saving measures and network optimization support long-term margin expansion.
- **China Recovery**: Slow but steady improvement in coatings demand, with strategic investments in Asia-Pacific.

**【CEO Summary Section】**
- **Q1 Highlights**: Revenue growth driven by Life Sciences (4% YoY) and Personal Care (stable despite Avoca divestiture). Specialty Additives faced softness in coatings and construction.
- **Strategic Priorities**: Innovation (e.g., TVO technologies, super wetting agents) and global expansion. Operational challenges include Calvert City unit delays and weather-related costs.
- **Market Outlook**: Optimism in second half with improving demand signals in North America and Europe. China coatings recovery expected to be gradual.

**【CFO Financial Commentary】**
- **Financial Performance**: Adjusted EBITDA $58M (down 5% YoY) due to operational disruptions. Free cash flow $125M, with $26M ongoing free cash flow. Guidance for FY26 EBITDA $400-420M, reflecting cost savings and strategic execution.
- **Operational Challenges**: Calvert City unit delays and weather-related costs ($11M impact). Recovery efforts underway, with HEC network optimization.

**【Q&A Highlights】**
- **China Coatings**: Bottoming out of demand, with focus on productivity and innovation. Globalize and innovate initiatives (e.g., biofunctionals, microbial protection).

Ashland Inc. (ASH) Q1 2026 Earnings Call Transcript

- **Resilient Q4 Results**: Adjusted EBITDA of $119M (25% margin) despite 8% sales decline, driven by portfolio optimization.
- **Growth Drivers**: Personal Care up 5% organically, Life Sciences pharma demand stable, Specialty Additives EBITDA flat YoY.
- **2026 Outlook**: 1%-5% sales growth, $400M-$430M EBITDA, >10% EPS growth from lower tax rate.
- **Innovation Momentum**: $15M incremental sales from innovation, TVO platform pipeline up 30%.
- **China Risks**: Coatings market remains weak, but Specialty Additives positioned for recovery.

**【CEO Summary Section】**
- **Q4 Performance**: Sales of $478 million (-8% YoY), adjusted EBITDA of $119 million (-4% YoY), driven by portfolio optimization. Comparable EBITDA grew 5% with margins expanding to 25%.
- **Business Unit Highlights**: 
  - *Life Sciences*: Resilient pharma demand, 32% EBITDA margin, new Vila sucrose launch.
  - *Personal Care*: 5% organic growth, biofunctional actives up double digits, 28.5% EBITDA margin.
  - *Specialty Additives*: EBITDA of $29 million (flat YoY), China coatings weakness offset by globalized gains.
- **2026 Outlook**: Sales $1.835B-$1.905B (1%-5% growth), EBITDA $400M-$430M, free cash flow >50% of EBITDA.

**【CFO Financial Commentary】**
- **Q4 Results**: GAAP net income $420M, Non-GAAP EPS $1.08 (vs. $1.24 prior year). Free cash flow $52M, liquidity $800M.
- **Cost Actions**: $30M restructuring savings ($20M realized in FY25), $60M manufacturing optimization ($5M savings in FY25, $18M expected FY26).
- **Tax Impact**: $103M tax refund from nutraceutical sale, reducing net leverage to mid-2s.
- **FY26 Guidance**: Adjusted EPS growth >10%, driven by lower tax rate and cost savings.

**【Q&A Highlights】**
- **Volumes & Pricing**: Globalized platforms (biofunctional actives, microbial protection) up double digits, offsetting China coatings weakness. Pricing stable in Life Sciences, 2% decline overall.
- **Innovation Pipeline**: $15M incremental sales from innovation in FY26, TVO platform driving 30%+ pipeline growth.
- **Capital Allocation**: $100M CapEx (50% growth projects), dividend payout ~30%, share buybacks contingent on leverage <2.5x.
- **China Recovery**: Specialty Additives expects stabilization in FY26, but no near-term recovery in coatings market.


Ashland Inc.(ASH)-20251105-2025 Q4 Earnings call transcript

- **Resilient Performance**: Q3 EBITDA $113M, 24.4% margin, 100% free cash flow conversion.
- **Cost Savings Momentum**: $60M manufacturing optimization ($5M in Q3, $55M+ in FY2026), restructuring ahead of schedule.
- **Innovation Success**: $10M+ incremental sales YTD, exceeding FY2025 target.
- **China Challenges**: Specialty Additives down 13% YoY, focusing on exports and innovation.
- **FY2025 Guidance**: Sales $1.825B-$1.85B, EBITDA $400M-$410M, reflecting cautious demand outlook.
- **No Tariff Impact**: No direct FY2025 impact, monitoring developments.


**【CEO Opening Remarks】**
- Q3 2025: Adjusted EBITDA of $113M (-19% YoY), stable margins at 24.4%, 100% free cash flow conversion.
- Strategic priorities: Cost savings ($60M manufacturing optimization), innovation (exceeding $10M in incremental sales), and portfolio focus on resilient consumer markets.
- FY2025 Guidance: Sales $1.825B-$1.85B, EBITDA $400M-$410M, reflecting cautious demand outlook.

**【CFO Financial Commentary】**
- Q3 Sales: $463M (-15% YoY), organic volumes down 4%, pricing stable.
- EBITDA: $113M (-19% YoY), margin 24.4% (-120bps YoY).
- EPS: $1.04M (-30% YoY), non-cash goodwill impairment $706M (no impact on liquidity).
- Cash: $800M+; net leverage 2.9x, disciplined capital allocation.

**【Business Unit Updates】**
- **Life Sciences**: $162M (-17% YoY), pharma growth 4%, EBITDA $54M (record margin). Innovation pipeline exceeds targets.
- **Personal Care**: $147M (-16% YoY), biofunctionals up double-digits, EBITDA $41M (high 20s margin). Sequential recovery in microbial protection.
- **Specialty Additives**: $131M (-13% YoY), China/MEAI drag offset by Performance Specialties growth. HEC network consolidation complete.

**【Operational Optimization】**
- Restructuring: $7.5M Q4 savings, $30M total by end FY2025.
- Manufacturing: $60M savings ($5M in Q3, $55M+ in FY2026). HEC consolidation benefits to flow through as inventory is sold.
- Tariffs: No direct FY2025 impact, monitoring developments.

**【Q&A Highlights】**
- **FY2026 Outlook**: Focus on self-help, stable demand in Personal Care, cautious on Specialty Additives/Intermediates. $55M+ manufacturing savings expected.
- **China Strategy**: Export-focused, regional innovation, long-term recovery potential.
- **Innovation**: $10M+ incremental sales YTD, targeting $25M+ in FY2026.
- **Tariffs**: Minimal direct impact, adjusting supply chain proactively.


Ashland Inc. (ASH) Q3 2025 Earnings Call Transcript

- **Q2 Results**: Sales down 17% YoY ($479M), EBITDA $108M (-14% YoY), driven by portfolio exits and macro weakness. 
- **Cost Savings**: $30M restructuring savings realized, $60M manufacturing optimization underway. 
- **Margins**: Life Sciences (32.6%), Personal Care (30.1%), Specialty Additives (19.4%) all at record levels. 
- **Tariff Impact**: $3-5M EBITDA drag in H2, 50%+ of at-risk sales mitigated. 
- **FY25 Guidance**: Sales $1.825B-$1.9B, EBITDA $400M-$420M, reflecting softer demand and macro uncertainty. 
- **Key Risks**: China overcapacity, U.S./Europe demand weakness, Intermediates pricing pressure. 
- **Growth Drivers**: Globalized strategy ($20M+ incremental sales), innovation pipeline ($100M+ by FY27). 


**【CEO Summary Section】**
- Q2 sales: $479 million (-17% YoY), driven by $67 million portfolio optimization impact and 5% organic decline due to lower volumes and pricing. 
- Adjusted EBITDA: $108 million (-14% YoY), with 22.5% margin (up 60 bps YoY). 
- Key initiatives: $30 million restructuring savings realized ahead of schedule, $60 million manufacturing optimization underway. 
- FY25 guidance updated to $1.825B-$1.9B sales and $400M-$420M EBITDA due to macroeconomic uncertainty. 
- Margins in Life Sciences (32.6%), Personal Care (30.1%), and Specialty Additives (19.4%) all improved YoY. 

**【CFO Financial Commentary】**
- Q2 GAAP net income: $420 million. 
- Adjusted EPS (excl. amortization): $0.99 (-22% YoY). 
- Free cash flow: -$6 million (typical Q2 seasonality). 
- Liquidity: $700+ million; net leverage: 2.8x. 
- Cost savings: $13M realized in Q2, $13M expected in H2. 
- Tariff impact: $3-5M EBITDA drag in H2, partially offset by FX gains. 

**【Q&A Key Highlights】**
- **Tariff Mitigation**: $70M U.S.-produced China sales at risk, but 50%+ mitigated via inventory, production shifts. VP&D most exposed. 
- **Specialty Additives**: China overcapacity persists, but North America/Europe volumes stable. 
- **Cash Flow**: Expect $150M-$200M free cash flow, dependent on inventory/FX. 
- **Intermediates**: March price increase, but margins remain pressured. 
- **Personal Care**: 30%+ margins sustainable, driven by cost savings and mix shift. 
- **Innovation**: $5M incremental sales YTD, targeting $100M by FY27. 
- **Paint Season**: Q3 outlook cautious due to soft demand in U.S./Europe. 
- **Customer Specific Issues**: Oral care timing, biofunctionals travel retail weakness. 


Ashland (ASH)-1 May 25-2025 Q2 Earnings call transcript

- **Q1 Results**: Sales $405M (-14% YoY), EBITDA $61M (-13% YoY), driven by portfolio changes and plant turnarounds.
- **Cost Savings Momentum**: $12M restructuring savings achieved, targeting $90M total savings by FY26.
- **Segment Performance**: Personal Care EBITDA +36%, Specialty Additives EBITDA +128%, offsetting pharma softness.
- **FY25 Guidance**: Sales $1.9-2.05B, EBITDA $430-470M, despite $7-8M currency headwinds.
- **Key Risks**: China export competition, European demand weakness, currency volatility.

**【CEO Opening Remarks】**
- Q1 sales: $405M (-14% YoY), driven by portfolio optimization (e.g., Nutraceutical divestiture). Excluding divestitures, organic sales down 3% YoY.
- Adjusted EBITDA: $61M (-13% YoY), impacted by $8M from portfolio optimization and $5M from extended plant turnarounds.
- Key initiatives: $90M cost savings target ($30M restructuring + $60M manufacturing optimization), with $12M already achieved in restructuring.
- Full year guidance reaffirmed: Sales $1.9-2.05B, EBITDA $430-470M.

**【CFO Financial Review】**
- Life Sciences: Sales $134M (-33% YoY), EBITDA $28M (-42% YoY) due to pharma inventory control and portfolio changes.
- Personal Care: Strong performance with 4% sales growth ($134M) and 36% EBITDA growth ($30M), driven by microbial protection and skin care.
- Specialty Additives: Sales $115M (-6% YoY), EBITDA $13M (+128% YoY) from higher production volumes.
- Free cash flow: Negative $26M (Q1 seasonal), targeting >50% conversion for FY25.

**【Business Unit Updates】**
- **Life Sciences**: Pharma volumes down high single digits YoY, but growth in injectables and OSD film coatings. Globalization pipeline expects 4 product launches in 2025.
- **Personal Care**: 4th consecutive quarter of EBITDA growth, microbial protection expansion in Brazil.
- **Specialty Additives**: Coatings demand weak in China/EMEA, but Performance Specialties up mid-single digits YoY.

**【Q&A Highlights】**
- **Q2 EBITDA Outlook**: Q1 is seasonally weakest; expect sequential improvement. Q2 guidance not provided, but FY25 targets reaffirmed.
- **Currency Impact**: Weaker EUR, CNY, BRL could reduce EBITDA by ~$7-8M FY25.
- **Trade Policy Risks**: Monitoring China export competition in HEC, VP&D. No material pre-buying observed.
- **Cost Savings Progress**: $12M restructuring savings achieved, targeting $20M+ FY25 savings.


Actual											0.84	0.81	1.25	0.94	1.05	1.22	1.22	0.88	1.5	1.89	1.46	0.97	1.43	1.23	0.41	0.45	1.27	1.49	1.26	0.28	0.99	1.04	1.08	0.26
Forecast											0.8273	0.8018	0.7076	0.6852	1.3272	1.3074	1.3245	0.8729	1.3738	1.6807	1.4519	0.9762	1.4653	1.3204	0.6868	0.1965	1.144	1.4476	1.2824	0.1697	1.1032	1.2049	1.2431	0.2385
Surprise	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	+1.54%	+1.02%	+76.65%	+37.19%	-20.89%	-6.69%	-7.89%	+0.81%	+9.19%	+12.45%	+0.56%	-0.64%	-2.41%	-6.85%	-40.30%	+129.01%	+11.01%	+2.93%	-1.75%	+65.00%	-10.26%	-13.69%	-13.12%	+9.01%

Actual	--	--	--	--	--	--	--	--	--	--	610.00M	574.00M	609.00M	552.00M	598.00M	637.00M	591.00M	512.00M	604.00M	644.00M	631.00M	525.00M	603.00M	546.00M	518.00M	473.00M	575.00M	544.00M	522.00M	405.00M	479.00M	463.00M	478.00M	386.00M
Forecast	--	--	--	--	--	--	--	--	--	--	618.75M	571.32M	594.03M	539.62M	636.41M	630.21M	626.54M	515.62M	591.61M	625.15M	626.77M	526.89M	625.96M	559.38M	528.57M	478.75M	574.64M	574.41M	524.07M	429.06M	502.62M	476.58M	482.30M	402.12M
Surprise	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-1.41%	+0.47%	+2.52%	+2.29%	-6.03%	+1.08%	-5.67%	-0.70%	+2.09%	+3.02%	+0.67%	-0.36%	-3.67%	-2.39%	-2.00%	-1.20%	+0.06%	-5.29%	-0.40%	-5.61%	-4.70%	-2.85%	-0.89%	-4.01%

ASH

ASH fundamentals

ASH Q1 2026 Earnings

Earnings Call

You can ask Aime

ASH

ASH fundamentals

ASH Q1 2026 Earnings

Earnings Call

ASH Earnings Call Summary for Q1/20269:00 AM on Feb 3, 2026

ASH Earnings Call Summary for Q4/20259:00 AM on Nov 5, 2025

ASH Earnings Call Summary for Q3/202510:00 AM on Jul 30, 2025

ASH Earnings Call Summary for Q2/202510:00 AM on May 1, 2025

ASH Earnings Call Summary for Q1/20259:00 AM on Jan 29, 2025

You can ask Aime